You are here

Prices & Quotes - UK Markets - Health Care Equipment & Services (4530)

Risk Warning The value of investments can fall as well as rise and any income from them is not guaranteed and you may get back less than you invested. Past performance is not a guide to future performance.

Down 7,670.94
Change Today:

Fusion Antibodies signs collaborative deal with US biotech firm

By Josh White

Date: Thursday 07 Oct 2021

LONDON (ShareCast) - (Sharecast News) - Preclinical antibody discovery and supply company Fusion Antibodies has signed a collaborative research and development agreement with an unnamed US-based biotechnology company which was recently incorporated to focus on a number of innovative early-stage antibody programmes, it announced on Thursday.
The AIM-traded firm said that under the agreement, it would provide its discovery and engineering services in relation to the research and development of several predetermined projects.

Based on the initial statement of work, Fusion would receive at least $1.83m in fees over the next two years for the provision of its initial agreed scope of services, which would use its 'RAMP' affinity maturation platform.

Depending on the outcome of that work, there was a framework for increased fees for service work within the agreement.

The client had already made an initial cash payment of $0.32m to Fusion on signing, with the remaining consideration payable at pre-agreed intervals.

Fusion said the deal was based on fixed deliverables and downstream milestones for the work, in addition to fees for service.

Should a product be successfully developed, registered and commercialised, the company said it would be fully entitled to royalty payments based on a percentage of sales figures of that product.

The client, which Fusion said it could not name for reasons of commercial sensitivity, was described as a biotechnology start-up that was specifically incorporated to pursue the projects to which Fusion would be providing services.

It said the client was financially backed by a US-based biotechnology investment company, which was active in life science investments.

"We are delighted to have agreed this important new contract with a key player in the biotech industry," said chief executive officer Richard Jones.

"The agreement has a minimum contract value of $1.83m, which is very significant.

"Furthermore, we are especially pleased that the project will take place using our RAMP platform, highlighting that this technology continues to gain traction in the marketplace."

At 1334 BST, shares in Fusion Antibodies were up 12.53% at 126.6p.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.


Price Data

Price 7,670.94
Change Today -126.70
03-Dec-21 Close 7,670.94

Top Risers

Price Change
Feedback 0.90p +12.5%
Surgical Innovations Group 2.40p +6.7%
Open Orphan 21.00p +6.1%
Abingdon Health 30.00p +5.3%
Induction Healthcare Group 55.00p +4.8%
Genedrive 40.50p +2.3%
Omega Diagnostics Group 26.50p +1.9%
Circassia Group 37.70p +1.9%
Kromek Group 13.00p +1.0%
CareTech Holding 572.00p +0.4%

Top Fallers

Price Change
MyHealthchecked 2.45p -3.9%
Novacyt S.A. (CDI) 352.30p -3.4%
Medica Group 160.00p -3.0%
Craneware 2,400.00p -2.8%
Integrated Diagnostics Holdings $1.29 -2.6%
Diaceutics 101.00p -2.4%
Mediclinic International 291.60p -2.2%
Polarean Imaging 55.00p -1.8%
Cambridge Cognition Holdings 121.50p -1.6%
Intelligent Ultrasound Group 16.75p -1.5%